TLDR: Firefly Bio has emerged from stealth mode with $94 million in funding co-led by Versant Ventures and MPM BioImpact. The company has assembled an “ADC dream team” to work on developing degrader-antibody conjugates (DACs), a new class of therapies to fight cancer. The team, led by CEO Scott Hirsch, includes scientists with backgrounds at Genentech, Merck & Co., and AbbVie, as well as Nobel laureate Carolyn Bertozzi. Firefly’s platform focuses on protein degraders, which use the cell’s natural degradation machinery to eliminate disease-causing proteins. The company aims to deliver a more selective payload that can improve the therapeutic index and clinical outcomes for patients.
Igniting Potential: $94M Funds Firefly Bio’s Protein Breakthrough with ADC Dream Team
Latest from Blog
VCFA Group Closes $1225M Venture Partners VII Fund
TLDR: VCFA Group closed VCFA Venture Partners VII fund with $122.5 million in commitments Transition marks continuation of VCFA’s pioneering legacy in the secondary private equity space VCFA Group, a pioneer in
VCFA Group’s Venture Partners VII Fund Raises $1225 Million
TLDR: VCFA Group closed its latest fund, VCFA Venture Partners VII, with $122.5 million in commitments. The fund focuses on smaller and more complex purchases of later-stage venture capital and growth equity
Revolutionizing Payments: $20M Raised for Stablecoin Network Development
TLDR: 1Money has raised over $20 million in seed funding to develop a stablecoin payments network. The network aims to offer instant transaction confirmation, low-cost fees, multicurrency support, compliance mechanisms, and scalability.
Top AI Trends and Startups Shaping 2025 and Beyond
“`html TLDR: Israel is excelling in applicative and vertical AI, focusing on practical solutions in cybersecurity, healthcare, and defense rather than competing with tech giants in foundational AI models. Five key AI
Sand Hill Road: Steve Vassallo’s Early Investment Edge at Foundation Capital
“`html TLDR: Steve Vassallo, a general partner at Foundation Capital, focuses on early-stage investments, often being the first institutional investor for startups. He emphasizes the importance of owning a significant stake in